CD8 IHC in CT-26 Tumour Model Reveals Treatment Effect

Study Overview
This pre-clinical case study presents CD8 IHC quantification in tissue from a CT-26 syngeneic mouse model, comparing a group treated with an anti-mCTLA4 reference compound versus a vehicle-treated group, to generate tissue-based evidence of mechanism of action for an internal oncology therapy.
Image analysis showed higher numbers of CD8⁺ cells in the treatment group and slower tumour volume growth versus controls.
Sample Details
CT-26 syngeneic mouse tumour model; anti-mCTLA4–treated group vs vehicle-treated group
Staining
IHC CD8 positive cell staining (DAB)
Analysis
All image analysis was performed using Indica Labs HALO.
View the Case Study
Click the thumbnail below to view the case study PDF:
Benefits of Working with OracleBio for your Clinical Studies:
- Data you can trust – We have thorough quality control procedures in place throughout our workflow to ensure the data we provide is of a high-quality standard.
- Work alongside Project managers – Experienced with ensuring data parity between time-separated batches of clinical samples.
Note: Permission has been granted for the use of this material
